Herboxidiene Features That Mediate Conformation-Dependent SF3B1 Interactions to Inhibit Splicing

被引:9
|
作者
Lopez, Adriana Gamboa [1 ,2 ]
Allu, Srinivasa Rao [3 ,4 ]
Mendez, Patricia [1 ,2 ]
Reddy, Guddeti Chandrashekar [3 ,4 ]
Maul-Newby, Hannah M. [1 ,2 ]
Ghosh, Arun K. [3 ,4 ]
Jurica, Melissa S. [1 ,2 ]
机构
[1] Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA
[2] Univ Calif Santa Cruz, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA
[3] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA
[4] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
D O I
10.1021/acschembio.0c00965
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Small molecules that target the spliceosome SF3B complex are potent inhibitors of cancer cell growth. The compounds affect an early stage of spliceosome assembly when U2 snRNP first engages the branch point sequence of an intron. Employing an inactive herboxidiene analog (iHB) as a competitor, we investigated factors that influence inhibitor interactions with SF3B to interfere with pre-mRNA splicing in vitro. Order-of-addition experiments show that inhibitor interactions are long lasting and affected by both temperature and the presence of ATP. Our data are also consistent with the model that not all SF3B conformations observed in structural studies are conducive to productive inhibitor interactions. Notably, SF3B inhibitors do not impact an ATP-dependent rearrangement in U2 snRNP that exposes the branch binding sequence for base pairing. We also report extended structure-activity relationship analysis of the splicing inhibitor herboxidiene. We identified features of the tetrahydropyran ring that mediate its interactions with SF3B and its ability to interfere with splicing. In the context of recent structures of SF3B bound to inhibitor, our results lead us to extend the model for early spliceosome assembly and inhibitor mechanism. We postulate that interactions between a carboxylic acid substituent of herboxidiene and positively charged SF3B1 side chains in the inhibitor binding channel are needed to maintain inhibitor occupancy while counteracting the SF3B transition to a dosed state that is required for stable U2 snRNP interactions with the intron.
引用
收藏
页码:520 / 528
页数:9
相关论文
共 50 条
  • [41] CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1
    Milan Hluchý
    Pavla Gajdušková
    Igor Ruiz de los Mozos
    Michal Rájecký
    Michael Kluge
    Benedict-Tilman Berger
    Zuzana Slabá
    David Potěšil
    Elena Weiß
    Jernej Ule
    Zbyněk Zdráhal
    Stefan Knapp
    Kamil Paruch
    Caroline C. Friedel
    Dalibor Blazek
    Nature, 2022, 609 : 829 - 834
  • [42] SF3B1 and the riddle of the ring sideroblast
    Gattermann, Norbert
    BLOOD, 2012, 120 (16) : 3167 - 3168
  • [43] The splicing factor SF3B1 is essential for proper alternative splicing and zygotic genome activation in early porcine embryos
    Zhao, Yanan
    Zhang, Hua
    Zhou, Benliang
    Wan, Runtian
    Yan, Yujun
    He, Rijing
    Yang, Xiaogan
    Sha, Qianqian
    Liang, Xingwei
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 282
  • [44] SF3B1 in Chronic Lymphocytic Leukemia
    Mori, Jinichi
    Takahashi, Yukie
    Tanimoto, Tetsuya
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (11): : 1057 - 1057
  • [45] Cancer-associated mutations in SF3B1 disrupt the interaction between SF3B1 and DDX42
    Zhao, Bo
    Li, Zhuang
    Qian, Rui
    Liu, Gang
    Fan, Mingyue
    Liang, Zehua
    Hu, Xin
    Wan, Youzhong
    JOURNAL OF BIOCHEMISTRY, 2022, 172 (02): : 117 - 126
  • [46] SF3B1: the lord of the rings in MDS
    Palomo, Laura
    Sole, Rings Francesc
    BLOOD, 2020, 136 (02) : 149 - 151
  • [47] SPLICING FACTOR 3B SUBUNIT 1 (SF3B1) REPRESENTS A NOVEL DRUGGABLE TARGET FOR MULTIPLE MYELOMA PATIENTS
    Ruberti, S.
    Soncini, D.
    Retali, V.
    Minetto, P.
    Contini, P.
    Rivoli, G.
    Passalacqua, M.
    Mastracci, L.
    Cagnetta, A.
    Nencioni, A.
    Todoerti, K.
    Neri, A.
    Gobbi, M.
    Lemoli, R. M.
    Cea, M.
    HAEMATOLOGICA, 2018, 103 : S26 - S26
  • [48] Mutant Splicing Factor 3b Subunit 1 (SF3B1) Causes Dysregulated Erythropoiesis and a Stem Cell Disadvantage
    Obeng, Esther A.
    McConkey, Marie E.
    Campagna, Dean
    Schneider, Rebekka K.
    Chen, Michelle C.
    Schmidt, Paul J.
    Mullally, Ann
    Fleming, Mark D.
    Ebert, Benjamin L.
    BLOOD, 2014, 124 (21)
  • [49] A Murine Model Harboring Cooperating DNMT3A and SF3B1 Mutations Phenocopies SF3B1 Driven Myelodysplastic Syndrome
    Wallace, Lashanale
    Leal-Cervantes, Ana
    Metidji, Amina
    Myers, Jacquelyn
    Rolle, Chandra
    Tillman, Heather
    Obeng, Esther A.
    BLOOD, 2022, 140 : 5862 - 5863
  • [50] Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes
    Volpe, Virginia O.
    Al Ali, Najla
    Chan, Onyee
    Padron, Eric
    Sallman, David A.
    Kuykendall, Andrew
    Sweet, Kendra
    Lancet, Jeffrey E.
    Komrokji, Rami S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (04) : 713 - 720